Michael Milbourne, MD, of New Life Cardiovascular in Wyndmoor, Pa., anuclear cardiologist in academic and private practice, is committed tooffering his patients outstanding, informed and proactive clinicalcare. In the last year, SPECT/CT has become an essential diagnostictool in Milbourne’s practice. 

PET/CTa technology whose potential is now being appreciated, but has yet to be fully realizedhas proven successful in the accurate staging and monitoring of oncology patient therapy for a variety of cancers. SPECT/CT, while relatively new, is beginning to make its mark in areas such as oncology, cardiology, neurology imaging. 

Diagnosing heart disease in women—the No. 1 cause of death of womenacross the globe—is sometimes difficult, but molecular PET and SPECTimaging is beginning to contribute to resolving this problem.

13N-ammonia, an established imaging probe for measuringmyocardial perfusion, has now been made available for use in thecommunity. This has thus far been difficult because of the shorthalf-life of 13N-ammonia of about 10 minutes. But even that time factor has been worked out.

John Griffith, CIO of Epic Imaging, Portland, Ore, says, “They asked us for it, and we had to come up with a solution.” The radiology practice provides imaging for close to 2,000 physician referrers; what they wanted was electronically delivered radiology reports sent to their practices not via fax, nor even over the Web, where they had to reside

As molecular imaging emerges from the cocoon of nuclear medicine, fueled by changes that have made it a vital technique for diagnosing disease and predicting and monitoring treatment response, training for physicians and technologists has made its way to the forefront for many education programs around the United States.

Dynamic contrast agent enhanced MRI (DCE MRI) is a fairly well-established technique that was first introduced in the early 1990s. Used in the pharmaceutical and clinical research environments, the post-processing algorithm evaluates dynamic images to measure contrast agent uptake in target tissue. 

Independent of one another, CT and PET have played important roles in the identification and staging of sarcomas. CTs anatomic capabilities have helped physicians locate sarcomas in patients, while PETs functional capabilities have assisted in monitoring treatment, grading sarcoma, separating benign from malignant masses, selecting biopsy sites, and assessing the extent of sarcomas.